146 related articles for article (PubMed ID: 35432631)
1. lncRNA CDKN2B-AS1 Could Be an Indicator to Identify Prognosis and Status of Immune Microenvironment in Thyroid Cancer.
Xue C; Yi C; Lin H; Zhao J; Yuan J; Chen Y; Chen H; Lin L; Zhao Y
Dis Markers; 2022; 2022():4317480. PubMed ID: 35432631
[TBL] [Abstract][Full Text] [Related]
2. Upregulated lncRNA Cyclin-dependent kinase inhibitor 2B antisense RNA 1 induces the proliferation and migration of colorectal cancer by miR-378b/CAPRIN2 axis.
Zheng Y; Zeng J; Xia H; Wang X; Chen H; Huang L; Zeng C
Bioengineered; 2021 Dec; 12(1):5476-5490. PubMed ID: 34511033
[TBL] [Abstract][Full Text] [Related]
3. Overexpressed lncRNA CDKN2B-AS1 is an independent prognostic factor for liver cancer and promotes its proliferation.
Zhuang H; Cao G; Kou C; Li D
J BUON; 2019; 24(4):1441-1448. PubMed ID: 31646789
[TBL] [Abstract][Full Text] [Related]
4. LncRNA CDKN2B-AS1 promotes the progression of ovarian cancer by miR-143-3p/SMAD3 axis and predicts a poor prognosis.
Xu C; Zhai J; Fu Y
Neoplasma; 2020 Jul; 67(4):782-793. PubMed ID: 32305052
[TBL] [Abstract][Full Text] [Related]
5. CDKN2B-AS1 as a novel therapeutic target in cancer: Mechanism and clinical perspective.
Hjazi A; Ghaffar E; Asghar W; Alauldeen Khalaf H; Ikram Ullah M; Mireya Romero-Parra R; Hussien BM; Abdulally Abdulhussien Alazbjee A; Singh Bisht Y; Fakri Mustafa Y; Reza Hosseini-Fard S
Biochem Pharmacol; 2023 Jul; 213():115627. PubMed ID: 37257723
[TBL] [Abstract][Full Text] [Related]
6. LncRNA DARS-AS1 regulates microRNA-129 to promote malignant progression of thyroid cancer.
Zheng W; Tian X; Cai L; Shen YM; Cao QS; Yang JY; Tian GY
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10443-10452. PubMed ID: 31841198
[TBL] [Abstract][Full Text] [Related]
7. Long non-coding RNA CDKN2B-AS1 promotes osteosarcoma by increasing the expression of MAP3K3 via sponging miR-4458.
Gui D; Cao H
In Vitro Cell Dev Biol Anim; 2020 Jan; 56(1):24-33. PubMed ID: 31950433
[TBL] [Abstract][Full Text] [Related]
8. Regulating of cell cycle progression by the lncRNA CDKN2B-AS1/miR-324-5p/ROCK1 axis in laryngeal squamous cell cancer.
Liu F; Xiao Y; Ma L; Wang J
Int J Biol Markers; 2020 Mar; 35(1):47-56. PubMed ID: 31960744
[TBL] [Abstract][Full Text] [Related]
9. LncRNA CDKN2B-AS1 contributes to glioma development by regulating the miR-199a-5p/DDR1 axis.
Lu J; Chen Y; Wen L; Zhou Q; Yan S
J Gene Med; 2022 Jan; 24(1):e3389. PubMed ID: 34559933
[TBL] [Abstract][Full Text] [Related]
10. LncRNA TNRC6C-AS1 regulates UNC5B in thyroid cancer to influence cell proliferation, migration, and invasion as a competing endogenous RNA of miR-129-5p.
Hou S; Lin Q; Guan F; Lin C
J Cell Biochem; 2018 Nov; 119(10):8304-8316. PubMed ID: 29893424
[TBL] [Abstract][Full Text] [Related]
11. Cancer stem cell-like cells-derived exosomal CDKN2B-AS1 stabilizes CDKN2B to promote the growth and metastasis of thyroid cancer via TGF-β1/Smad2/3 signaling.
Wu Q; He Y; Liu X; Luo F; Jiang Y; Xiang M; Zhao R
Exp Cell Res; 2022 Oct; 419(1):113268. PubMed ID: 35750242
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of LncRNA FOXD3-AS1 suppresses the aggressive biological behaviors of thyroid cancer via elevating miR-296-5p and inactivating TGF-β1/Smads signaling pathway.
Chen Y; Gao H; Li Y
Mol Cell Endocrinol; 2020 Jan; 500():110634. PubMed ID: 31678422
[TBL] [Abstract][Full Text] [Related]
13. Long non-coding RNA SLC16A1-AS1: its multiple tumorigenesis features and regulatory role in cell cycle in oral squamous cell carcinoma.
Feng H; Zhang X; Lai W; Wang J
Cell Cycle; 2020 Jul; 19(13):1641-1653. PubMed ID: 32450050
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA NR2F1-AS1 promoted proliferation and migration yet suppressed apoptosis of thyroid cancer cells through regulating miRNA-338-3p/CCND1 axis.
Guo F; Fu Q; Wang Y; Sui G
J Cell Mol Med; 2019 Sep; 23(9):5907-5919. PubMed ID: 31304680
[TBL] [Abstract][Full Text] [Related]
15. The stimulative function of long noncoding RNA CDKN2B-AS1 in osteosarcoma by targeting the microRNA-122/CCNG1 axis.
Abula A; Saimaiti G; Maimaiti X; Wuqikun W; Abulaiti A; Ren P; Yusufu A
J Recept Signal Transduct Res; 2022 Feb; 42(1):71-79. PubMed ID: 33283575
[TBL] [Abstract][Full Text] [Related]
16. CDKN2B antisense RNA 1 expression alleviates idiopathic pulmonary fibrosis by functioning as a competing endogenouse RNA through the miR-199a-5p/Sestrin-2 axis.
Yang M; Yin E; Xu Y; Liu Y; Li T; Dong Z; Tai W
Bioengineered; 2022 Mar; 13(3):7746-7759. PubMed ID: 35291918
[TBL] [Abstract][Full Text] [Related]
17. CDKN2B-AS1: An Indispensable Long Non-coding RNA in Multiple Diseases.
Song C; Qi Y; Zhang J; Guo C; Yuan C
Curr Pharm Des; 2020; 26(41):5335-5346. PubMed ID: 32767927
[TBL] [Abstract][Full Text] [Related]
18. lncRNA ZNF674-AS1 inhibits the migration, invasion and epithelial-mesenchymal transition of thyroid cancer cells by modulating the miR-181a/SOCS4 axis.
Le F; Li HM; Lv QL; Chen JJ; Lin QX; Ji YL; Yi B
Mol Cell Endocrinol; 2022 Mar; 544():111551. PubMed ID: 34990740
[TBL] [Abstract][Full Text] [Related]
19. LncRNA CDKN2B-AS1 relieved inflammation of ulcerative colitis via sponging miR-16 and miR-195.
Tian Y; Cui L; Lin C; Wang Y; Liu Z; Miao X
Int Immunopharmacol; 2020 Nov; 88():106970. PubMed ID: 33182065
[TBL] [Abstract][Full Text] [Related]
20. Silencing lncRNA CDKN2B-AS1 Alleviates Childhood Asthma Progression Through Inhibiting ZFP36 Promoter Methylation and Promoting NR4A1 Expression.
Chen Z; Fan N; Shen G; Yang J
Inflammation; 2023 Apr; 46(2):700-717. PubMed ID: 36422840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
